Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International : J&J, other drugmakers to face trial in California over claims they fueled opioid epidemic

04/19/2021 | 06:00am EDT

April 19 (Reuters) - Four drugmakers are set to face trial on Monday in a lawsuit by several large counties in California that are seeking more than $50 billion over claims the companies helped fuel an opioid epidemic by deceptively marketing addictive painkillers.

The case against Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Endo International PLC and AbbVie's Allergan unit is one of the thousands of lawsuits by states and local governments seeking to hold pharmaceutical companies responsible for the drug crisis.

Opioids have resulted in the overdose deaths of nearly 500,000 people from 1999 to 2019 in the United States, according to U.S. Centers for Disease Control and Prevention.

The populous Santa Clara, Los Angeles and Orange counties and the city of Oakland accuse the companies of deceptively marketing painkillers in ways that downplayed their addictive risks. The drugmakers argue they acted appropriately and that they did not cause the epidemic.

If Orange County Superior Court Judge Peter Wilson finds the companies liable following a non-jury trial, the counties say the companies should have to pay $50 billion to cover the costs of abating the public nuisance they created plus penalties.

More than 3,400 similar lawsuits are pending nationally over the opioid epidemic. The only other case to go to trial in the opioid litigation resulted in the state of Oklahoma in 2019 winning a $465 million judgment against J&J, which is appealing.

Other cases are slated to go to trial in the coming months, creating new pressure for the companies to reach settlements.

The nation's three largest drug distributors - McKesson Corp , AmerisourceBergen Corp and Cardinal Health Inc - and J&J have proposed paying a combined $26 billion to resolve the cases against them. The proposed deal has not been finalized. (Reporting by Nate Raymond in Boston; Editing by Daniel Wallis)


© Reuters 2021
All news about ENDO INTERNATIONAL PLC
08:26aENDO INTERNATIONAL  : Tennessee Court Of Appeals Issues Orders Regarding State C..
AQ
06/11ENDO INTERNATIONAL  : Tennessee Court Of Appeals Issues Orders Regarding State C..
AQ
06/10ENDO INTERNATIONAL PLC  : Submission of Matters to a Vote of Security Holders, F..
AQ
06/09ENDO INTERNATIONAL  : Paladin Labs Inc. Announces Approval of Wakix® (pitolisant..
AQ
05/17ENDO INTERNATIONAL  : Citigroup Adjusts Price Target on Endo International to $1..
MT
05/10ENDO INTERNATIONAL  : RBC Cuts Price Target on Endo International to $6 From $7,..
MT
05/07ENDO INTERNATIONAL  : 2020 Irish Statutory Accounts
PU
05/07ENDO INTERNATIONAL  : Management's Discussion and Analysis of Financial Conditio..
AQ
05/07ENDO INTERNATIONAL  : Q1 2021 Endo International plc Earnings Conference Call
PU
05/06ENDO : Q1 Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2021 2 722 M - -
Net income 2021 122 M - -
Net Debt 2021 6 766 M - -
P/E ratio 2021 9,94x
Yield 2021 -
Capitalization 1 460 M 1 460 M -
EV / Sales 2021 3,02x
EV / Sales 2022 2,92x
Nbr of Employees 3 397
Free-Float 98,5%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 7,70 $
Last Close Price 6,26 $
Spread / Highest target 91,7%
Spread / Average Target 23,0%
Spread / Lowest Target -52,1%
EPS Revisions
Managers and Directors
NameTitle
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations
Sector and Competitors